Fasting Glucose, Glucose Excursion, Glycemic Control
Conditions
Keywords
dapagliflozin, fasting glucose, postprandial glucose excursion, euglycemic hyperinsulinemic clamp, euglycemic oral glucose tolerance test
Brief summary
Dapagliflozin is a highly selective, reversible and potent inhibitor of the sodium-glucose-linked Transporter 2 (SGLT2), which was successfully investigated for its use as a treatment option in type 2 diabetes mellitus. The effect of dapagliflozin is an increased glucosuria, and it was shown that mean blood glucose concentrations and postprandial glucose excursion in special were significantly reduced in type 2 diabetic patients. Due to its mechanism-of action it seems likely that also type 1 diabetic patients will benefit from dapagliflozin. The present study is focused on the effects of dapagliflozin on fasting glucose homeostasis and postprandial glucose excursion in male type 1diabetic patients. Participants will subsequently receive 10 milligrams of dapagliflozin and placebo for 3 days (equals 2 x 30mg per cross-over period) in a double-blind, randomised, cross-over design. The effects will be measured via euglycemic hyperinsulinemic clamp studies (fasting glucose homeostasis) and euglycemic oral glucose tolerance clamp tests (postprandial glucose excursions).
Interventions
DRUGDapagliflozin
euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
Sponsors
Medical University of Graz
University of Bern
Medical University Innsbruck
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Type 1 diabetes mellitus (duration of disease at least 5 years) * C-peptide concentration \< 0.2µg/l * male sex * aged 18 to 60 years * Body Mass Index 20 - 25 kg/m2 * no measurable, clinically relevant ketonuria
Exclusion criteria
* insufficient venous status on both forearms * renal and/or hepatic insufficiency (including microalbuminuria and/or albumin/creatinin-ratio) * history of cancer * intake of medication and/or substances capable to influence insulin sensitivity within the last 3 months prior to study inclusion * alcohol- and/or drug abuse, nicotine consumption \> 5 cigarettes / 24h * brittle-diabetes * history of severe hypoglycemia, defined as the need for foreign assistance independent of actual blood glucose concentration measured * history or evidence of any other clinically significant disorder, condition or disease other than those outlined above that, in the opinion of the investigator may compromise the ability of the participant to give written informed consent, would pose a risk to subject safety, or interfere with the study evaluation, procedures or completion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| fasting glucose homeostasis | study visit, immediatly | During hyperinsulinemic, euglycemic clamp studies, fasting glucose homeostasis will be determined for both, dapagliflozin and placebo. |
| postprandial glucose homeostasis | study visit, immediatly | During euglycemic oral glucose tolerance clamp tests, postprandial glucose excursion will be determined and compared between dapagliflozin and placebo. |
Countries
Austria
Outcome results
None listed